Newsroom
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
Press Releases
Media Contact:
Maya Frutiger
Head of Corporate Communications
maya.frutiger@us.sumitomo-pharma.com
2023
-
Jul. 31, 2023Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
-
Jul. 10, 2023Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities
-
Apr. 26, 2023Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder
-
Apr. 3, 2023Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
-
Mar. 10, 2023Sumitovant Biopharma Completes Acquisition of Myovant Sciences
-
Jan. 19, 2023Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options
2022
-
Dec. 1, 2022Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder
-
Nov. 14, 2022Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season
-
Aug. 5, 2022Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain associated with Endometriosis
-
Jul. 5, 2022Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
-
Jun. 17, 2022Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 2 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women with Endometriosis-Associated Pain
-
Apr. 22, 2022Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
-
Feb. 9, 2022Sunovion and Otsuka Initiate Phase 3 Clinical Development of Non-Racemic Amisulpride for the Treatment of People with Bipolar Depression
2021
-
Oct. 8, 2021Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
-
Sep. 30, 2021Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
-
Jun. 29, 2021Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder
-
May 26, 2021Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
-
Apr. 12, 2021Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
- Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
-
Mar. 29, 2021Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for RELUGOLIX for the Treatment of Advanced Prostate Cancer
-
Feb. 17, 2021Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Feb. 16, 2021HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
-
Jan. 5, 2021Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
2020
-
Dec. 28, 2020Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
-
Dec. 23, 2020Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
-
Dec. 18, 2020Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
-
Dec. 10, 2020Sunovion Highlights Data from its Late-Stage Psychiatric Medicine Pipeline at the American College of Neuropsychopharmacology (ACNP) Annual Meeting 2020
-
Jul. 6, 2020Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
-
May 29, 2020Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
-
Apr. 15, 2020New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia
-
Mar. 31, 2020Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.